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Abstract
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral death in infants. Reduced CD8 T-cells and
negligible interferon gamma (IFNc) in the airway are associated with severe infant RSV disease, yet there is an abundance of
alveolar macrophages (AM) and neutrophils. However, it is unclear, based on our current understanding of macrophage
functional heterogeneity, if immature AM improve viral clearance or contribute to inflammation and airway obstruction in
the IFNc-deficient neonatal lung environment. The aim of the current study was to define the age-dependent AM
phenotype during neonatal RSV infection and investigate their differentiation to classically activated macrophages (CAM)
using i.n. IFNc in the context of improving viral clearance. Neonatal and adult BALB/cJ mice were infected with 16106
plaque forming units (PFU)/gram (g) RSV line 19 and their AM responses compared. Adult mice showed a rapid and robust
CAM response, indicated by increases in major histocompatibility complex class II (MHC II), CD86, CCR7, and a reduction in
mannose receptor (MR). Neonatal mice showed a delayed and reduced CAM response, likely due to undetectable IFNc
production. Intranasal (i.n.) treatment with recombinant mouse IFNc (rIFNc) increased the expression of CAM markers on
neonatal AM, reduced viral lung titers, and improved weight gain compared to untreated controls with no detectable
increase in CD4 or CD8 T-cell infiltration. In vitro infection of J774A.1 macrophages with RSV induced an alternatively
activated macrophage (AAM) phenotype however, when macrophages were first primed with IFNc, a CAM phenotype was
induced and RSV spread to adjacent Hep-2 cells was reduced. These studies demonstrate that the neonatal AM response to
RSV infection is abundant and immature, but can be exogenously stimulated to express the antimicrobial phenotype, CAM,
with i.n. rIFNc.
Citation: Empey KM, Orend JG, Peebles RS Jr, Egan˜a L, Norris KA, et al. (2012) Stimulation of Immature Lung Macrophages with Intranasal Interferon Gamma in a
Novel Neonatal Mouse Model of Respiratory Syncytial Virus Infection. PLoS ONE 7(7): e40499. doi:10.1371/journal.pone.0040499
Editor: Malcolm Gracie Semple, University of Liverpool, United Kingdom
Received November 23, 2011; Accepted June 12, 2012; Published July 6, 2012
Copyright:  2012 Empey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project described was supported by the National Institutes of Health through Grant Numbers KL2 RR024154 and KL2TR000146, Central Research
Development Fund from the University of Pittsburgh Research Council, and resources provided by the University Of Pittsburgh School Of Pharmacy, Pittsburgh,
Pennsylvania. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kme33@pitt.edu (KME); jay.kolls@chp.edu (JKK)
Introduction
Respiratory syncytial virus (RSV) is the primary cause of infant
bronchiolitis and the most frequent cause of viral death in infants
worldwide. According to the World Health Organization, there
are 64 million cases of RSV each year resulting in 160,000 deaths
globally. In the United States, annual RSV infection results in
approximately 1.5 million outpatient visits among children ,5
years of age with 75,000–125,000 estimated hospitalizations
related to RSV among children aged ,1 year, emphasizing the
importance of age at initial infection [1,2]. Despite the global
burden of RSV disease, there remains no vaccine and no effective
treatment. Disease pathology has been linked to host immune
responses, which differs markedly in infants and adults [3,4]. The
critical role of CD8 T-cell and interferon gamma (IFNc)
production in adult RSV clearance has been well described [5–
8]. Conversely, severity of infant RSV infection coincides with a
deficient adaptive cytotoxic T-cell response and negligible IFNc
production [4,9–11]. In the absence of a mature and efficient
lymphocyte response, viral clearance in the infant airway is
thought to rely more heavily on immature innate immune
responses mediated largely by macrophages and neutrophils [4].
However, strikingly little is known regarding the phenotype and
function of immature infant alveolar macrophages (AM) in the
skewed T-helper 2 (Th2) cytokine (IFNc-deficient) lung environ-
ment.
Far from our original understanding that all macrophages are
pro-inflammatory, the concept of macrophage functional hetero-
geneity has gained considerable ground over the past decade [12].
Classical activation of macrophages differentiated by IFNc and
Toll-like receptor (TLR)-binding pathogens, including RSV, was
historically believed to be the only pathway of macrophage
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40499
activation. Classically activated macrophages (CAM) are charac-
terized by production of nitric oxide (NO), secretion of interleukin-
12 (IL-12), IL-1, IL-6, macrophage inflammatory protein-alpha
(MIP-1a), and monocyte chemotactic protein-1 (MCP-1), and
increased expression of major histocompatibility complex class II
(MHC II), CD86, CCR7, cyclooxygenase-2 (COX2) and reduc-
tion in mannose receptor (MR) expression [13–15]. This pro-
inflammatory response increases intracellular killing of phagocy-
tosed organisms and promotes recruitment of additional antimi-
crobial cells, often at the expense of increased tissue damage.
Alternatively activated macrophages (AAM), induced by IL-4 and
IL-13, promote tissue repair through clearance of apoptotic
cellular debris [13]. They also secrete the anti-inflammatory
cytokine, IL-10 and produce arginase-1 that competes with
inducible nitric oxide synthase (iNOS), rendering them useless in
the killing of intracellular pathogens. Shirey and colleagues
recently published a model for the role of AAM during RSV
infection in adult rodents, which showed an immediate increase in
CAM followed by a later rise in AAM through secretion of IL-4
and IL-13 from AM themselves [16]. This model provides a timely
and critical explanation regarding how Th2-type cytokines may be
released in the absence of T-cell infiltration in the infant airway
during RSV infection. Yet, the extent to which CAM expression
and anti-viral function occur in the RSV-infected infant lung in
the absence of T-cell-derived IFNc remains unknown. It also
remains unclear if the promotion of AAM without the balance of
CAM expression in the Th2 skewed, RSV-infected infant lung
would remain protective or promote immunopathogenesis due to
delayed viral clearance. To this end, we tested the hypothesis that
RSV infection would result in increased CAM expression in adult
mice due to the abundance of lymphocyte-derived IFNc, but
CAM expression would be reduced in neonatal mice with
negligible IFNc production. We further hypothesized that
intranasal (i.n.) IFNc would increase neonatal CAM expression
during RSV infection leading to a reduction in viral load and
improved weight gain.
We used an immunologically relevant neonatal mouse model of
RSV infection to more closely recapitulate the human infant
airway and an in vitro macrophage cell (J774A.1) line to further link
the functional response of CAM following IFNc priming. Similar
to human infants, our infant mouse model demonstrated reduced
lymphocyte infiltration, deficient endogenous IFNc production,
and a dominant macrophage response following RSV infection.
Compared to RSV infected BALB/c adult mice, neonatal mice
did not express CAM and had delayed viral clearance. Following
treatment with i.n. IFNc, RSV-infected, neonatal AM showed
significantly increased expression of CAM markers, expedited
RSV clearance and improved weight gain with no apparent
increase in CD4 or CD8 T cell lung infiltration or activation. In
vitro, RSV infection alone induced an AAM phenotype in J774A.1
macrophages and mediated the spread of virus to Hep-2 cells.
However, when macrophages were first primed with IFNc, cells
expressed a CAM phenotype and the viral spread to adjacent
Hep-2 cells was significantly reduced.
Materials and Methods
Ethics
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Mice
were housed at The University of Pittsburgh Division of
Laboratory Animal Resources. These animal experiments were
approved by The University of Pittsburgh Institutional Animal
Care and Use Committee (IACUC), approved protocol number
1103468 and mice were handled according to IACUC guidelines.
All efforts were made to minimize animal suffering.
Mice and viral preparation
Pathogen-free breeder BALB/cJ mice were purchased at 5–
7 wks of age from The Jackson Laboratory (Bar Harbor, ME) and
were maintained in specific pathogen-free facilities. Female mice
were cohoused for 2 wks to synchronize estrus for timed
pregnancies. Additional pathogen-free, non-breeder female
BALB/cJ mice were purchased at 8 weeks of age from The
Jackson Laboratory for infection and control adult groups
described below. Guidelines were followed for the care and use
of animals as indicated by our animal review board. The line 19
subtype of RSV was provided by Dr. Martin Moore, Emory
University, Atlanta, GA. RSV line 19 was passed through 4
rounds of plaque purification for generation of master stocks;
working stocks were propagated in HEp-2 cells (American Type
Culture Collection) and titered in HEp-2 cells using standard
hematoxylin-eosin (H&E) plaque assays, as previously described
[17]. Viral stocks were quick-frozen in alcohol/dry ice and stored
at 280uC. Uninfected HEp-2 cell cultures were similarly
processed to obtain a control, virus-free, mock preparation,
referred to as cell lysate or mock. Viral stocks and HEp-2 cell
lines were assessed to be free of mycoplasma and other common
contaminants using the Plasmo Test Mycoplasma Detection Kit
(InvivoGen) according to manufacturer’s instructions. Lung titers
were determined, as previously described, within one month of
sterile removal and storage of infected lungs at 280uC [17]. Mice
are considered neonates at less than 7 d of age and will be referred
to in figures as pups.
Histopathology
Heart-lung blocks were harvested 7 days post-infection (dpi) and
fixed in 4% paraformaldehyde overnight. The lungs were
transferred to 70% ethanol and then embedded in paraffin blocks.
Tissue sections were stained with periodic acid-Schiff (PAS) to
assess goblet cell hyperplasia as a measure of mucin expression.
Slides were examined and scored by a single pathologist (T.O.)
who was blinded to experimental groups. Individual airways were
scored for goblet cell hyperplasia according to the following scale:
0 = no PAS positive cells; 1 = 1–25% PAS positive cells; 2 = 25–
50% PAS positive cells; 3 = 50–75% PAS positive cells; 4 = 75–
100% PAS positive cells. All airways involved in the tissue sections
were scored.
Infection protocol
Neonatal and adult mice were infected with a high dose/high
volume (HD/HV) inoculation of RSV line 19. Between two to
four days of age, neonates were infected intranasally under
isoflurane anesthesia with a HD/HV of 16106 plaque forming
unit (PFU)/gram (g) body weight of RSV line 19 in 10 microliters/
g of body weight. Adult mice (8–9 weeks of age) were anesthetized
with intramuscular (IM) ketamine 40 ug/g and xylazine 6 ug/g.
They were simultaneously infected with 16106 PFU/g body
weight of RSV line 19 in 9 microliters/g of body weight. Mock-
infected mice were inoculated simultaneously with virus-free cell
lysates in the respective volumes described above for neonates and
adults. When held upright with the neck fully extended, the mice
readily inhaled the stock virus placed over their nostrils with a
micropipette. Following infection, mice were evaluated until full
recovery from anesthesia. All adults and 92% (55 of 60) of
neonates survived the infection protocol; this is similar to the
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survival rate for our standard volume (adults = 50 ml; neo-
nates = 10–12 ml) infection protocols.
IFNc administration
Two groups of neonatal mice, two to four days of age, were
infected with HD/HV RSV line 19. Recombinant murine IFNc
(rIFNc) or diluent (0.1% mouse serum in PBS) was administered to
neonatal mice intranasally as previously described [18]. Briefly,
RSV-infected (RSV+) and mock-infected (mock) neonates received
16 ng/g rIFNc (Peprotech, Rocky Hill, NJ) diluted in 10 ml of
0.1% mouse serum/PBS on 1, 3, 5, and 7 dpi. Groups are as
follows: 1) RSV-infected/rIFNc-treated=RSV/rIFNc+; 2) RSV-
infected/diluent only =RSV/rIFNc2; 3) Mock-infected/rIFNc-
treated =mock/rIFNc+; 4) Mock-infected/diluent only =mock/
rIFNc2. The mock/rIFNc2 control group was from a separate
experiment with age-matched (two to four day-old) BALB/cJ
mice.
Isolation of lung interstitial and alveolar cells
Lung cells were prepared as previously described [19]. Briefly,
adult and neonatal lungs were lavaged with five washes (for final
volumes of 5 and 1.5 to 3 ml, respectively) of cold HBSS-EDTA
(3 mM). Left lung lobes were used for viral titers; right lung lobes
were used for flow cytometry analysis. Briefly, they were excised,
weighed, minced, and enzyme treated at 37uC for 1 h in RPMI
1640 medium containing 3% fetal calf serum, 50 U/ml DNase
(Sigma-Aldrich), and 1 mg/ml collagenase A (Sigma-Aldrich).
Digested lung tissues were pushed through mesh screens to obtain
a single-cell suspension. Red blood cells (RBCs) were lysed by
treatment with a hypotonic buffer, and the cells were then
resuspended in HBSS for enumeration and phenotypic analysis by
flow cytometry.
Flow cytometry
Surface protein expression and intracellular cytokine secretion
were determined by flow cytometry. Isolated aliquots of 56105 to
106 cells from lung lavage and digest were resuspended in staining
buffer (16PBS, 0.1% BSA, 0.02% sodium azide) and centrifuged
at 1200 rpm for 8 min, at 4uC. After removal of supernatants, cells
were blocked with anti-CD16/32 (BD Biosciences) for 15 minutes.
Cells were stained with appropriate combination panels of
fluorochrome-conjugated antibodies (Abs) specific for murine
CD11b-perCpCy5.5, CD86-v450, major histocompatibility com-
plex (MHC) class II (MHC II; I-ad)-FITC, and CD4-FITC, and
CD62L-V450 (BD Biosciences, Mountain View, CA); CD11c-PE-
Cy7, CD8a-APC, and CD44-PE (eBiosciences, San Diego, CA);
and (mannose receptor) MR-Alexa Fluor 647 (AbD Serotec), as
well as their isotype controls. Prior to staining MR, cells were
treated with Leucoperm according to manufacturer’s instructions
(AbD Serotec). Cells were washed (26) with staining buffer, fixed
with 0.5% paraformaldehyde and analyzed within 12 hours;
analysis showed all tandem dyes remained intact following
fixation. Labeled cells were analyzed with an LSRII flow
cytometer system (BD Biosciences). For figures in which cell
numbers are given, percentage of the gated cell subset for each
sample was multiplied by the number of cells manually counted by
hemocytometer. FlowJo software (Tree Star Inc. Ashland, OR)
was used to analyze the data.
Cytokine and chemokine analysis
Neonatal and adult lungs were lavaged with 1.5–3 mls and 5 ml
respectively, of HBSS/3 mM EDTA; bronchoalveolar lavage fluid
(BALF) was stored at 280uC until analysis. Lung supernatants
were assayed for IFNc, IL-12p40, IL-6, TNFa, MCP-1, IL-10,
and IL-4 using mouse inflammation multiplex assays (Bio-Rad,
Hercules, CA) according to manufacturer’s instructions. The
plates were read using a LuminexH 200TM Total System machine
(Luminex Corp, Austin, Tx). The data were analyzed using the
LDS1.7 Software.
Infection center assay
The mouse macrophage cell line, J774A.1 (TIB-67) was
purchased from ATCC and cultured according to recommended
specifications. Cells were seeded in 12-well plates at a concentra-
tion of 16104 cells/well and allowed to adhere. In separate
experiments, cells were primed with 165 ng/ml of rIFNc, 10 ng/
ml each of IL-4/IL-13 (Peprotech, NJ), or media only for 24 hours
after which time the priming solutions were removed. The cells
were then immediately infected with RSV line 19 (generous gifts
from Dr. Stokes Peebles, Vanderbilt University and Dr. Martin
Moore, Emery University) at a multiplicity of infection (MOI) of
0.05. The cells were rocked for 3 hours, then overlaid with Hep-2
cells and incubated for 5 hours. The cells were then covered with
methylcellulose and incubated for 5 days at which time a standard
H&E staining protocol was followed. Control wells consisted of
C1) BLANK, C2) J774A.1+, RSV+, rIFNc2, C3) J774A.12,
RSV+, rIFNc+, C4) J774A.1+, RSV2, rIFNc+.
Real-Time Polymerase Chain Reaction (PCR)
J774A.1 macrophages were seeded in 12-well plates at a
concentration of 16104 cells/well and allowed to adhere as
described for the infection center assay. In separate experiments,
cells were infected with RSV line 19 alone at a MOI of 3 or were
first primed with 100 ng/ml of rIFNc, prior to RSV infection;
control wells received media only in all experiments. mRNA was
isolated from cells harvested at 24 hour and 72 hours post-
infection using RNeasy Mini Qiagen Kit (Life Technologies, NY)
and quantified using a NanoDropH spectrophotometer (Invitro-
gen, NY). The mRNA was reverse transcribed to cDNA using a
Superscript III First-strand synthesis Supermix for qRT-PCR kit
(Life Technologies, NY) and quantified on a 7500 ABI Fast RT-
PCR system (Life Technologies). Pre-mixed Taqman primer and
probes using a Fam/Tamara reporter/quencher combination
were purchased from ABI specific for Arginase-1, mannose
receptor (MRC-1), FIZZ1, iNOS, and COX-2. Results are
represented as a relative increase from media only or from
media+IFNc, using the delta, delta ct method indicating fold
change over the house keeping gene (GAPDH). Data are
compared to control wells treated with media only using a paired
T-test for 3–4 wells per group.
Statistical Analysis
Data are expressed as the mean 6 SD of at least five mice per
group and each experiment was repeated at least twice. Statistics
were performed using GraphPad Prism 5 Software (La Jolla, CA).
A two-way ANOVA was used to compare differences among data
collected at days post-infection between neonatal and adult groups
and between IFNc-treated and IFNc- neonatal groups and
J774A.1 primed or unprimed groups, followed by a Bonferroni
post-test. A paired student’s t-test was used to compare viral titers
for IFNc-treated versus non-treated pups to show a less rigorous
analysis, as the analysis at each time point was not dependent on
the previous time point. A linear regression analysis was used to
compare the slopes of RSV versus mock infected pup weights as a
percent change of original weight over time using GraphPad Prism
5 Software. A Student t-test was used to determine the difference
Inhaled IFNc in RSV-Infected Infant Mice
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between average values of the slopes between the two groups; R2
values for each fitted line was $0.9.
Results
Infection of neonatal BALB/cJ mice with RSV line 19
effectively models human infant RSV infection
To validate our neonatal mouse model as an effective tool for
evaluating human infant AM responses to disease, viral load was
quantified from neonatal and adult BALB/cJ mouse lungs
following RSV line 19 infection. Virus was delivered to the upper
and lower airways (data not shown) using a high dose/high volume
(HD/HV) inoculum of 16106 PFU/g of RSV in 9 ml and 10 ml/g
of diluent in adults and neonates, respectively. Mice were
inoculated at two to four days and eight to nine weeks of age in
three separate experiments. Viral titers were quantified from left
lung lobes on 0, 2, 4, 7, and 10 dpi from four to six mice per age
group at each time point; the same dosing strategy was used in all
subsequent experiments. Adult viral lung titers peaked at 4 dpi
and become undetectable after 7 dpi (Fig. 1A). Neonatal lung
titers showed persistent growth through 10 dpi, suggesting lower
peak titers, but extended viral replication in infant compared to
adult mouse airways. Daily weights were monitored for signs of
illness. A characteristic bimodal weight loss pattern was observed
in adult mice following RSV line 19 as is common with RSV A2
[20], yielding a peak weight loss of ,20% total body weight by
7 dpi (Fig. 1B). To account for continuous weight gain in infant
mice of about ,1 g every 1–2 days, linear regression analysis was
used. Weight data from each of three repeat experiments (15 pups
per group) showed a moderate, but significant divergence in
growth rates between RSV-infected and mock-infected neonatal
mice (Fig. 1C).
Mucus production is a hallmark of severe infant RSV disease
and has been shown to inhibit macrophage phagocytosis [21]. To
determine if our neonatal mouse model of RSV infection
demonstrated increased mucus production, we compared PAS-
staining in RSV- and mock-infected neonatal and adult lungs.
Lungs were harvested at 7 dpi, a time frame in which viral load is
elevated and neonatal mouse weights were beginning to diverge
among infected animals (Fig. 2A–B). A morphometric scale
(Materials and Methods) shows more airways were producing
mucin in RSV line 19-infected compared to mock-infected
animals. RSV-infected neonatal mice had a greater relative
expression of inspissated mucin lining the surface of bronchoe-
pithelial cells. In contrast, adult mucin appeared intracellular, with
little to no secretion observed. Together, these data demonstrate
active RSV infection in infant BALB/c mice with increased mucus
production and weight loss that serves as an effective model for
testing immune modulating anti-RSV treatments, such as inhaled
IFNc.
Innate immune cells, rather than CD8 T-cells,
predominate during neonatal RSV infection
Despite the well-established role of CD8 T-cells in RSV
clearance reported in adult mice, recent evidence in human
infants suggests innate immune cells, namely macrophages and
neutrophils, may be more critical to viral clearance due to the
absence of an efficient lymphocyte response [4]. To determine
dominant cell population(s) during RSV infection, differential cell
counts from BALF were determined at 7 dpi in four to six
neonatal and adult animals. This time point represents the nadir of
weight loss in infected adult animals, the divergence in weights
among RSV- and mock-infected neonatal mice, and initial viral
clearance among both age groups. Macrophages (96%) were the
predominant cell type in RSV- and mock-infected neonatal mice
(Fig. 3A). Conversely, RSV-infected adult animals responded with
a significant increase in lymphocyte (16%) and neutrophil (11%)
infiltration relative to mock-infected controls. To elucidate the
effect of age on cellular infiltration following RSV infection, total
cells were enumerated and compared in neonatal and adult BALF
and lung tissue on 0, 2, 4, 7, and 10 dpi following RSV or mock
infection. Total cells in neonate compared to adult lungs were
significantly increased on 7 and 10 dpi in RSV- compared to
mock-infected groups; however, the relative increase in the
neonatal group was minimal (Fig. 3B, F). Cells did not enter the
airways until 10 dpi in both neonatal and adult animals, and once
again, cell numbers increased only minimally in infant airways
(Fig. 3C, G), suggesting little cellular recruitment to the lung. To
better understand the age-dependent infiltration of T-cells
entering the lung at 7 dpi, neonatal and adult lungs were
harvested following RSV- or mock- infection for analysis by flow
cytometry. Adult animals responded to RSV infection with a
robust increase in the percent of CD8 T-cells compared to mock-
infected animals by 7 dpi in both the lung and BALF; no increases
in CD4 T-cells were detected (Fig. 3D–E). Conversely, neonatal
Figure 1. Effective infection of pup and adult mice with RSV
line 19. Adult (8–9 wks old) and pup (2–4 days old) BALB/cJ mice
received a HD/HV inoculum of RSV line 19 or cell lysate. Serial viral titers
were determined by standard H&E plaque assay (A). Daily weights were
measured in adults (B) and pups (C). For linear regression analysis, pup
data are representative of 3 separate experiments with 15 pups per
group. For viral titers and adult weights, data are representative of 3
experiments and points represent data for at least 5 mice per group 6
SD. *, Significant compared with mock groups at p,0.05.
doi:10.1371/journal.pone.0040499.g001
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mice showed a modest increase in percent CD4 T-cells and CD8
T-cells relative to adult animals infected with RSV (Fig. 3H–I).
Together, these data demonstrate that adult animals have a more
robust lymphocyte response to RSV infection compared to
neonatal animals. Regardless of age, lymphocytes appeared to
be retained in the lung and failed to reach significant levels in the
alveolar space until 10 dpi.
It has been postulated that AM are more important for viral
clearance in the RSV-infected infant airway due to age-related
deficiencies in CD8 T-cell responses, known to be critical for viral
clearance in adult lungs [4,5]. Thus, we interrogated the age-
dependent cellular distribution of AM and lymphocytes following
RSV infection. Neonatal and adult mice were infected with RSV
or mock-infected as previously described. Single cell suspensions
were stained with primary conjugated antibodies commonly used
to discriminate AM (CD11b2/CD11c+high cells) and dendritic
cells (DC) (CD11b+/CD11c+ cells) from lungs and BALF
harvested at 0, 2, 4, 7, and 10 dpi and analyzed by flow cytometry
[22]. Infection of adult BALB/cJ mice with RSV resulted in a
rapid and continuous increase in the percent of DC with a
simultaneous decrease in percent of AM which persisted through
10 dpi (Fig. 4A–D). Infection of neonatal mice with the same
weight-based inoculum of RSV resulted in a transient peak in DC
percentage at 4 dpi that rapidly subsided by 7 dpi with a
concomitant increase in the percent of AM. By 10 dpi, AM
approached 80% of total large cells in the airways of both RSV-
and mock-infected neonatal animals suggesting the transient viral
effects observed at 4 dpi were rapidly usurped by age-depended
factors in order to achieve sufficient AM numbers (Fig. 4E–H).
Together these data confirm that AM are the predominant cell
type in the infant mouse model of RSV infection.
Differential expression of cytokines following RSV
infection indicates an early anti-inflammatory lung
environment in infant compared to adult mice
RSV disease and early age of infection are independently
associated with a Th2-type cytokine response, hallmarked by
increased IL-4 and/or reduced IFNc production [23,24]. To
better understand the age-dependent cytokine environment that
drives AM differentiation or result from AM activation, cytokines
were measured by Luminex analysis in neonatal and adult BALF
harvested at 2, 4, and 7 dpi. Following RSV infection, adult mice
produced a significant increase in IFNc and a modest increase in
IL-4 which appeared to coincide with increases in lymphocyte
infiltration into the lung at 7 dpi (Fig. 5A–B). Increases in
cytokines associated with CAM, including MCP-1, IL-6, and IL-
12, increased rapidly after RSV infection in adult animals
(Fig. 5D–E); no increase in IL-10 was observed. Conversely,
infection of neonatal mice with the same weight-based dose of
RSV resulted in an absence of IFNc, coupled with increases in IL-
4 and IL-10 (Fig. 5G–I). Moreover, neonatal mice produced no
detectable increases in MCP-1 or IL-6 and delayed and reduced
levels IL-12p40 in response to RSV infection (Fig. 5J–L). These
data suggest lymphocyte-derived IFNc and moderate IL-4 levels
are produced in response to RSV infection in adult animals as well
as a robust early pro-inflammatory response. In neonatal mice,
IFNc production is absent but IL-4 and IL-10 increase by 2 dpi,
long before lymphocyte infiltration into the lung, suggesting a non-
lymphocyte source of IL-4.
Neonatal BALB/cJ mice express an immature, age-
dependent AM phenotype following RSV infection
The functional heterogeneity of AM is driven primarily by
pathogens and environmental IFNc and IL-4 ratios; disruption of
influences that control the CAM and AAM balance could have
severe consequences on airway inflammation and resolution of
Figure 2. RSV line 19 induces pulmonary mucin expression in adult and pup BALB/cJ mice. Adult (8–9 wks old) and pup (2–4 days old)
BALB/cJ mice received a HD/HV inoculum of RSV line 19 or cell lysate. The lungs were harvested at 7 dpi and sections were stained with PAS. Airways
were scored 0 to 4 for PAS positivity (Materials and Methods). Twenty to 42 airways were scored per mouse. (A) Examples of airway mucin scores.
Bright pink PAS-positive cells can be visualized in RSV-infected adult and pup sections. (B) Total numbers of mice and airway scored for each group
are shown. The pie charts indicate the mucin scores ranked as a percentage of total airways from the respective groups.
doi:10.1371/journal.pone.0040499.g002
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infection [25,26]. Based on our findings that the ratio of IL-4 to
IFNc was greater in neonatal compared to adult animals following
RSV infection, we sought to compare age-dependent AM
phenotypes following RSV- or mock-infection. To determine the
extent to which RSV induced CAM in neonatal versus adult
BALB/cJ mice, the expression of surface markers indicative of
CAM: MHCII, CD86, CCR7 and AAM: MR were quantified
following isolation of AM from BALF harvested at 0, 2, 4, 7, and
10 dpi [12,15,27]. RSV infection of adult animals resulted in a
robust increase in the expression of MHC II and CD86 and to a
lesser degree CCR7; these marked changes in combination with a
significant reduction in MR is suggestive of a CAM phenotype
(Fig. 6A–D). Conversely, RSV infection of neonatal animals
resulted in a striking absence of AM differentiation (Fig. 6E–H). A
significant, but moderate increase in MHC II at 10 dpi suggested
neonatal AM are activated in a delayed and deficient manner
Figure 3. Age-dependent cellular response to RSV line 19. Adult
(8–9 wks old) and pup (2–4 days old) BALB/cJ mice received a HD/HV
inoculum of RSV line 19 or cell lysate. (A) At 7 dpi BALF was collected, H
& E stained, and 200 cells per slide were counted using a 1006 oil
emersion objective lens. Data are depicted as percent of total cells that
are macrophages (Mac), neutrophils (Neu), eosinophils (Eos), and
lymphocytes (Lym). Cells were isolated from adult (B–C) and pup (D–
E) BALF (C, G) and digested lung tissue (B, F). Total cells were quantified
on 2, 4, 7, and 10 dpi by hemocytometer. Cells in adult (D–E) and pup
(H–I) digested lung tissue were stained with anti-CD4 (D, H) and anti-
CD8 (E, I) and analyzed by flow cytometry on 2, 4, and 7 dpi. Mean
values 6 SD are depicted, and statistical difference was defined as a P
value.05 for differences between groups at the same time point (*); data
are representative of two separate experiments.
doi:10.1371/journal.pone.0040499.g003
Figure 4. Recruitment and activation of neonatal antigen
presenting cells is delayed following RSV infection. Adult (8–
9 wks old) and pup (2–4 days old) BALB/cJ mice received a HD/HV
inoculum of RSV line 19. The animals were lavaged at 0, 2, 4, 7, and
10 dpi. The percent of immune cell subtypes were analyzed by flow
cytometry in adult (A–D) pup (E–F) BALF, including CD11b2 CD11c+
high (nonlymphocyte gate) (A, E) and CD11b+ CD11c+ (nonlymphocyte
gate) (B, F). Dot plots are representative of at least five mice per group
for mock adults at 7 dpi (C), RSV adults (D), mock pups (G), and RSV
pups (H). Mean values 6 SD are depicted, and statistical difference was
defined as a P value.05 for differences between groups at the same time
point (*); data are representative of three separate experiments.
doi:10.1371/journal.pone.0040499.g004
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relative to adults during RSV infection (Fig. 6E). Moreover, an
apparent ontologic shift toward a resting AAM phenotype was
observed in both RSV- and mock-infected animals as indicated by
reduced CCR7 and increased MR (Fig. 6G–H). When similar
measurements were made on digested lung tissues, equivalent
trends in MHC class II, CD86, CCR7, and MR expression were
observed in tissue macrophages of adult and neonatal BALB/cJ
mice infected with RSV or mock-infected (Fig. S1). Together,
these data suggest RSV line 19 induces CAM in adult mice, but
fails to effectively induce classical activation in immature neonatal
AM, likely due to the absence of IFNc.
Inhaled rIFNc expedites viral clearance in RSV-infected
neonatal mice
We previously observed delayed viral clearance in our neonatal
BALB/cJ mouse model of RSV infection in the absence of
endogenous of INFc compared to adult animals. Thus, we sought
to determine if treatment with i.n. rIFNc would then expedite the
RSV clearance in our infant RSV mouse model. Mice were RSV-
or mock-infected between two to four days of age as previously
described. Mice within each of these groups were treated with i.n.
rIFNc or diluent on 1, 3, 5, and 7 dpi. To assess potential toxicity
Figure 5. Neonatal mice produced early anti-inflammatory
cytokines in response to RSV. Adult (8–9 wks old) and pup (2–4
days old) BALB/cJ mice were infected with HD/HV RSV line 19 or cell
lysate, then lavaged with 5 ml or 1.5–3 ml of cold HBSS/EDTA,
respectively at the indicated dpi. The first wash of each lavage was
reserved and frozen for analysis by luminex multiplex assay. Adult (A–F)
and pup (G–L) cytokine concentrations were measured at 2, 4, and
7 dpi. Dashed lines represents limits of quantification (LOQ) for the
assay; if no dashed line given, all points are above the LOQ. Mean values
6 SD are depicted, and statistical difference was defined as a P value .05
for differences between mock-infected animals at the same time point
(*); data are representative of two separate experiments.
doi:10.1371/journal.pone.0040499.g005
Figure 6. Neonatal BALB/cJ mice express an immature, age-
dependent AM phenotype following RSV infection. Adult and
pup BALB/cJ mice were infected with HD/HV RSV line19 or cell lysate.
Cells were isolated from pup and adult BALF on 0, 2, 4, 7, and 10 dpi.
The percent of immune cell subtypes were analyzed by flow cytometry
in adults (A–D) pups (E–F), including MHC II (A, E), CD86 (B, F), CCR7 (C,
G), and MR (D, H) on the CD11b2 CD11c+ high gate. Mean values6 SD
are depicted, and statistical difference was defined as a P value .05 for
differences between mock-infected animals at the same time point (*);
data are representative of two separate experiments.
doi:10.1371/journal.pone.0040499.g006
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due to rIFNc, daily weights were compared among treated and
untreated mice. Lungs and BALF were harvested at the indicated
days pi. No weight loss in the RSV line 19 or mock-infected groups
due to rIFNc was observed; rather a significant increase in weight
gain was observed in the RSV/rIFNc+ group (Fig. 7A). Increased
levels of IFNc in BALF among treated mice indicated inhaled
cytokine delivery was an effective method of administration
(Fig. 7B). To determine the effect of rINFc on RSV clearance,
viral lung titers were quantified by plaque assay. A more
conservative 2-way ANOVA was used to analyze the results
indicating a significant reduction in viral burden at 2 dpi
compared to untreated mice (Fig. 7C). Considering the apparent
decrease in viral load observed at 4 and 7 dpi, separate paired t-
tests were used to analyze viral titers at each time point, showing
significant reductions in viral titers at 2, 3, 4, and 7 dpi (Fig. 7D).
These data determined that inhaled delivery of rIFNc reduced
RSV lung titers by a log-fold reduction and effectively expedited
viral clearance to within 7 dpi (Fig. 7C) compared to untreated
animals, in which titers extended beyond 10 dpi (Fig. 1A).
Inhaled rIFNc increases CAM activation in RSV-infected
neonatal BALB/cJ mice without T-cell activation
RSV-infected infants are prone to Th2-type cytokine responses.
Reduced IFNc and increased IL-4 and IL-13 have been attributed
to immature host immune responses combined with the RSV
organism itself, thought to induce Th2 cytokines from CD4 T
cells, mast cells, basophils, and monocytes [4,28,29]. Thus, despite
its macrophage stimulating properties in mature adults, the extent
to which i.n. IFNc induces CAM in RSV-infected, neonatal lungs
cannot be assumed and remains largely unknown. To assure i.n.
rIFNc wasn’t depleting the intended target cell population, AM
were analyzed in BALF harvested on 4, 7, and 10 dpi from two to
four day-old mice infected with RSV or mock-infected and treated
with rIFNc or diluent on 1, 3, 5, and 7 dpi as described above.
Cell differential counts showed the RSV/rIFNc+ group main-
tained a higher total number of macrophages compared to the
RSV/rIFN- group at 4 dpi. Compared to lymphocytes, macro-
phages remained a dominant cell population in the RSV-infected
infant airway (Fig. 8A–C). Despite increased viral clearance in the
rIFNc-treated group, total T-cell infiltration and activation was
not increased compared to untreated animals on or before the
time of increased viral clearance (Fig. 8B, D–H). To determine
extent of CAM in RSV- and mock-infected neonatal mice treated
with i.n. rIFNc in AM (CD11b2/CD11c+ cells), cells were
isolated and processed for flow cytometry from BALF harvested at
4, 7, and 10 dpi. As previously described, MHC II, CD86, CCR7,
and MR expression were quantified over time in treated and
control animals. RSV-infected mice treated with rIFNc had
significantly increased expression of CD86 by 4 dpi, MHC II was
increased by 7 dpi and by 10 dpi CD86, MHC II and CCR7
expression was significantly increased and MR was reduced
compared to untreated mice, indicating induction of a CAM
phenotype (Fig. 9A–C, E–F). A multiplex cytokine analysis was
performed on cytokines commonly produced by CAM in the
BALF of RSV/rINFc+ animals compared to RSV/rINFc-
animals. Similar to adult animals infected with RSV in
Figure 5D–F, RSV-infected neonatal mice treated with IFNc
had increased production of IL-12p40, IL-6, and TNFa (Fig. S2).
Moreover, no increase in IL-4 or IL-10 was observed following
IFNc as was previously shown in untreated infant mice. These
data demonstrate that exogenous treatment with inhaled rIFNc
can overcome immaturity of AMs in a neonatal mouse model of
Figure 7. Inhaled rIFNc reduces viral load in RSV-infected neonatal BALB/cJ mice. On 1, 3, 5, and 7 dpi pups received 16 ng/g of i.n. rIFNc
or diluent only. (A) Daily weight change compared to weight prior to infection was plotted; (B) IFNc was measured from BALF by Luminex assay. Viral
titers were measured from left lung lobes by H&E plaque assay on 2, 3, 4, 5, and 7 dpi. RSV titers were analyzed by a 2-way ANOVA and graphically
represented with a line graph (C) and by paired t-test, which is graphically represented by a bar graph (D). Mean values 6 SD are depicted, and
statistical difference was defined as a P value .05 for differences between mock-infected animals at the same time point (*); data are representative of
two separate experiments.
doi:10.1371/journal.pone.0040499.g007
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RSV infection as measured by increased CAM expression of
CD11b2/CD11c+ cells, increased production of IL-12p40, IL-6,
and TNFa, and expedited viral clearance.
Priming RSV-infected J774A.1 macrophages with IFNc
changes the expression phenotype from AAM to CAM
and reduces the spread of virus to adjacent Hep-2 cells
To determine if CAM contribute to RSV clearance, viral spread
from infected J774A.1 murine macrophages to adjacent Hep-2
cells was examined. Briefly, J774A.1 macrophages were primed
with rIFNc, IL-4/IL-13 or media only, washed, infected with RSV
line 19 at an MOI of 0.05 for 3 hours, and then overlaid with
Hep-2 cells. After 5 hours, the cells were covered with methylcel-
lulose and incubated for 5 days followed by standard H&E
staining. Plaques represented RSV that had replicated in
macrophages and infected adjacent Hep-2 cells. In vitro priming
of J774A.1 macrophages with rIFNc significantly reduced the
number of RSV line 19 plaques compared to media-primed
macrophages, in Hep-2 cells by at least 50 PFU per well (Fig. 10A).
Conversely, in a separate experiment, J774A.1 macrophages
primed with IL-4/IL-13 significantly increased the spread of virus
to Hep-2 cells, presumably through a reduction in nitric oxide
involved in intracellular killing of organisms (Fig. 10B). To assess
changes in iNOS expression and other markers often used to
discriminate between CAM and AAM, real-time PCR was used to
measure message expression in J774A.1 cells after RSV infection
(Fig. 10C). Greater increases in the expression of MR and
arginase-1 compared to Cox-2 and iNOS indicate AAM
differentiation in J774A.1 cells infected with RSV after 24 hours.
By 72 h pi a greater increase in fold expression of MR and
arginase-1 over iNOS and Cox2 was observed (Fig. 10D). When
J774A.1 macrophages were primed with IFNc prior to RSV
infection, iNOS expression increased markedly over arginase-1
after 24 h, indicating CAM differentiation (Fig. 10E), which likely
contributed to the reduced spread of virus to adjacent Hep-2 cells.
Interestingly, priming with IFNc alone was not sufficient to
differentiate CAM, suggesting that RSV binds TLR on macro-
phages and provides an adequate secondary signal for CAM
differentiation in mature J774A.1 macrophages. By 72 h after
IFNc priming, Arginase-1 and MR once again increased,
indicating AAM expression resumes (Fig. 10F). Together, these
data show that treatment of neonatal mice with i.n. rIFNc not only
reduces RSV lung titers by , a log-fold reduction/gram of lung,
but also expedites RSV clearance by 3 days in infant mice without
causing weight loss. In vitro data support our hypothesis that i.n.
rIFNc induces CAM in the presence of RSV infection and
contributes to viral clearance.
Figure 8. rIFNc does not increase CD4 or CD8 T-cell activity in RSV-infected infant mice. Pup (2–4 days old) BALB/cJ mice received a HD/
HV inoculum of RSV line 19 followed by 16 ng/g of i.n. rIFNc (RSV/rIFNc+) or diluent only (RSV/rIFNc-) on 1, 3, 5, and 7 dpi. Control groups were
mock-infected with cell lysate followed by16 ng/g of i.n. rIFNc (mock/rIFNc+) or diluent only (mock/rIFNc 2) on 1, 3, 5, and 7 dpi. BALF and lungs
were collected at each time point. Cells were isolated from BALF, H & E stained, and 200 cells per slide were counted using a 1006 oil emersion
objective lens. Data are depicted as Total number of cells that are macrophages (Mac) (A), lymphocytes (Lym) (B), and neutrophils (Neu) (C);
eosinophils were negligible. Lungs were enzyme digested, stained with fluorochrome-labled antibodies specific CD4, CD8, CD44, and CD62L, and
analyzed by flow cytometry (E–H); all cells were first gated by small forward and side scatter (D). Bars represent data for at least five mice per group
from two experiments. Mean values 6 SD are depicted, and statistical difference was defined as a P value .05 for differences between groups at the
same time point (*).
doi:10.1371/journal.pone.0040499.g008
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Discussion
The aim of the current study was to define the age-dependent
AM phenotype during neonatal RSV infection and investigate
their differentiation to CAM using i.n. rIFNc in the context of
improving viral clearance. To accomplish this, a neonatal mouse
model of RSV infection was developed based on five critical
criteria regarding severe human infant RSV disease: 1) severe
disease occurs when virus enters the lower airway, 2) mucus
production is increased, 3) lymphocyte infiltration is minimal, 4)
IFNc production is negligible, and 5) there is an abundance of AM
[4,30–32]. The HD/HV inoculum is not a physiologic method of
human infant infection; however, in our neonatal mouse model,
this method introduced more virus to the lower airway compared
to standard low volume methods which leaves more virus in the
upper airway and nasal septum (data not shown). A similar
method using 99m Technetium sulfur colloid in four-week-old mice
also demonstrated improved delivery to the lungs compared to the
nasopharynx [17]. Moreover, in adult animal models, Lukacs et al,
showed the RSV line 19 subtype induced significantly more mucus
production than the A2 strain commonly studied in rodent models
[30,32]. Using these strategies, our neonatal mice maintained
consistent viral lung titers compared to adult mice, which
coincided with reduced weight gain (Fig. 1A–C) and increased
PAS staining in neonatal and adult lungs (Fig. 2). These findings
confirm that this model is an effective tool for studying immature
infant host responses to RSV infection and targeted immune
modulating RSV treatment strategies.
CD8 T-cells are critical in the response to RSV infection
leading to both viral clearance and illness in adult mouse models
[5]. In our neonatal mouse model we showed that macrophages
were dominant in the infant airway with markedly reduced levels
of CD8 T-cells compared to adults. Interestingly, adult animals
had a predominant CD8 T-cell response, whereas infant mice did
not. Coupled with significantly increased levels of IFNc and IL-
12p40, these data indicate a strong anti-viral cytotoxic T-cell
response in adult animals, which was markedly reduced in
neonatal mice. This immature lymphocyte response has been
implicated in the dominant AM and neutrophil response observed
Figure 9. Inhaled rIFNc increases CAM activation in RSV-infected neonatal BALB/cJ mice. Pup (2–4 days old) BALB/cJ mice received a HD/
HV inoculum of RSV line 19 followed by 16 ng/g of i.n. rIFNc (RSV/rIFNc+) or diluent only (RSV/rIFNc2) on 1, 3, 5, and 7 dpi. Control groups were
mock-infected with cell lysate followed by 16 ng/g of i.n. rIFNc (mock/rIFNc+) or diluent only (mock/rIFNc 2) on 1, 3, 5, and 7 dpi. Cells were isolated
from BALF on 4, 7, and 10 dpi and percent CD11b2 CD11c+ (nonlymphocyte gate) (A), CD11b+CD11c+ (nonlymphocyte gate) (D), and MHC II, MR,
CD86, and CCR7 (gated on CD11b2 CD11c+ cells) (B, C, E, F) were determined by flow cytometry. Points represent data for $5 mice per group6 SD.
({) indicates P,0.05 for comparisons between RSV/rIFNc+ and RSV/rIFNc2; ({) indicates p,0.05 for comparisons between mock/rIFNc+ and mock/
rIFNc2; (*) indicates p,0.05 for comparisons between RSV/rIFNc+ and mock/rIFNc+.
doi:10.1371/journal.pone.0040499.g009
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in human infants with severe RSV disease [4,9]. Welliver and
colleagues analyzed lung tissue from infants with fatal cases of
RSV and showed almost a complete absence of CD8 T-cells and
NK cells coupled with an abundance of macrophages and
neutrophils [4]. A similar study by Johnson and colleagues
evaluated the histopathology of four fatal, untreated human
infants with acute RSV infection [31]. They observed a majority of
AM around the bronchioles, alveolar interstitium and airspaces. In
our study, direct comparison of RSV-infected neonatal and adult
animals emphasized the deficient lymphocyte and abundant AM
response among neonatal mice and corroborates the findings in
human RSV-infected infants (Fig. 3–4) [4]. Based on differential
cell counts in the BALF at 7 dpi, 16% of the total cells in the adult
BALF were lymphocytes compared to 1% in neonatal BALF.
Similarly, there were significantly more CD8 T-cells in RSV-
infected (17%) compared to mock-infected (7%) adult lungs versus
neonatal RSV-infected (9%) and mock-infected (4%) lungs by
7 dpi, which coincided with an overall reduction in total cellular
airway infiltration (Fig. 3). While some lymphocyte infiltration into
infant lungs was apparent following RSV infection (albeit less than
adults) the cells did not appear to migrate into the airway. Delayed
migration of T-cells into infant airways was also recently reported
by Lines and colleagues in a neonatal mouse model of influenza
virus, indicating an age-dependent delay in cellular migration to
the alveolar space during infection; despite i.n. administration of
exogenous IFNc, neonatal T cells could not be drawn into the
airway before two weeks post-infection in this model [33].
Lymphocyte-derived cytokines, IFNc and IL-4, increased in
adult BALF in concert with the infiltration of lymphocytes into the
lung at 7 dpi; however, IFNc levels did not increase in RSV-
infected compared to mock-infected neonatal mice. Interestingly,
neonatal IL-4 levels increased very early by 2 dpi indicating that
Figure 10. IFNc-primed J774A.1 macrophages reduce the spread of RSV to adjacent cells. The mouse macrophage cell line, J774A.1, was
cultured in vitro and primed with rIFNc or media (A) or IL-4/IL-13 or media (B) prior to infecting with line 19 RSV for 3 hours. Infected cells were
overlaid with Hep-2 cells and culture for 5 hours, covered with methylcellulose, incubated for 5 days and a standard H&E stain; plaques are reported
as PFU per well. (C) Relative quantification by real-time PCR was performed on RNA extracted from cells infected with RSV line and presented as the
fold expression over cells not infected with RSV; all assays were normalized to GAPDH. (D) Relative quantification by real-time PCR was performed on
RNA extracted from cells primed with IFNc and infected with RSV and presented as the fold expression over cells cultured in media alone (E–F); all
assays were normalized to GAPDH. For infection center assays, data represent the mean 6 SD of 12 wells per treatment and each control arm
(Materials and Methods). For RT-PCR, data represent the mean 6 SD of 4 wells per treatment and each control arm Statistical difference was defined
as a P value .05 for differences between groups (*); data are representative of two separate experiments.
doi:10.1371/journal.pone.0040499.g010
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although production was not significantly increased, it had to be
from a non-lymphocyte source. Shirey et al. recently published
evidence in adult rodents suggesting that AM themselves are
capable of IL-4 and IL-13 production, leading to the continuous
promotion of an AAM phenotype and increased IL-10 production.
While we did not observe an increase in IL-13 production, we did
observe an early increase in the anti-inflammatory cytokine IL-10
in neonatal mice by 2 dpi, which was absent in adult animals. It is
intriguing to consider that the innate host immune response is
capable of initiating and maintain a Th2-type cytokine in the
absence of T-cells. Increasing evidence to this effect is being
realized, although the extent and the consequences in the infant
airway remain unclear [34]. A balance of CAM and AAM in the
absence of adaptive immunity may be critical to keep viral
replication in check. Additional cytokines representative of CAM
were increased early post-infection in adult animals compared
with mock-infected animals, including MCP-1, IL-6, and IL-
12p40. Neonatal mice failed to increase production of these
cytokines, but for IL-12p40 which was delayed and reduced in its
production relative to adult animals (Fig. 5). These cytokines were
evaluated in total BALF and do not discriminate between
macrophage-derived, or other acute response cell types, including
DC, or airway epithelial cells. However, production of neonatal
IL-12p40 does not occur until 7 dpi as DC are rapidly declining
and AM are significantly greater than mock-infected controls.
These data do not exclude the potential contribution of DC in the
neonatal host immune response to RSV disease. However,
together these data conclude that the neonatal AM phenotype
and cytokine response are anti-inflammatory following RSV
infection and their potential for targeted immunotherapy requires
further investigation.
There is growing interest in AM as a potential vaccine or
therapeutic target for severe neonatal RSV disease [35,36].
However, understanding the age-dependent changes in AM
functional heterogeneity, driven largely by IFNc and IL-4, is
critical to advancing this line of research. Using adult rodent
models, Shirey and colleagues showed RSV A2 stimulation of
primary cultured BALB/c BAL macrophage induced an early
increase in CAM indicators, including iNOS, IL-12p40, and
COX-2 [16]. Markers of AAM, Arginase-1, FIZZ1, and MR were
constitutively elevated and increased later during viral infection,
suggesting adult AM are responsible for both viral clearance and
containment of a robust inflammatory response. In our neonatal
mouse model, CAM was significantly impaired following RSV
infection relative to adults. Rather, we observed an age-dependent
increase in MR expression and uniform decrease in CCR7
expression through 10 dpi regardless of RSV infection (Fig. 5G–
H). Increased MR expression with increasing age suggests the
neonatal AM are achieving a resting steady state despite the added
insult of RSV infection, likely due to an increased IL-4 to IFNc
ratio [37]. In the developing post-natal airway, this may serve as
an important protective mechanism to avoid damaging inflam-
matory responses in lieu of added infection risks. In an attempt to
balance the IL-4/IFNc ratio in the RSV-infected neonatal airway,
treatment of neonatal mice with i.n. rIFNc significantly increased
the CAM phenotype in RSV-infected neonatal mice without
causing weight loss (Fig. 9); in fact, treatment moderately
improved weight gain (Fig. 7). The increased CAM phenotype
was greater in RSV-infected animals treated with IFNc compared
to mock-treated animals suggesting the effect was not due to IFNc
alone. Macrophage-derived cytokines, IL-12p40, IL-6, and TNFa
were also increased in the RSV/rIFNc+ compared control group
indicating the combination of secondary stimulation with RSV
induced greater activation than either virus or IFNc alone (Fig.
S2). Total neutrophil counts were significantly increased at 7 and
10 dpi in the RSV/rIFNc+ group. Neutrophil infiltration has been
implicated as a contributing factor in airway obstruction in severe
RSV disease [4], thus some caution is warranted for consideration
of IFNc as a vaccine or therapeutic tool in infant RSV disease.
Total lymphocytes were also increased by 10 dpi, however, this
was well after RSV clearance had occurred suggesting lympho-
cytes played a minor, if any role in IFNc-induced viral clearance in
the neonatal mouse model (Fig. 8A). The reduction in viral load
and improved weight gain increased in concert with CAM
suggesting that i.n rIFNc-induced macrophage activation contrib-
uted, at least in part, to viral clearance (Fig. 7 and 9).
We have demonstrated that neonatal AM are abundant in the
neonatal BALB/cJ airway following RSV infection, similar to
human infants, and their immature phenotype likely contributes to
viral spread in the IFNc-deficient lung environment. However,
discriminating viral infection of AM versus phagocytosis of RSV or
RSV-infected cells remains difficult. The pathology of acute RSV
infection reported from four human infants showed that most AM
were immunostain-positive for RSV suggesting AM associate with
RSV in vivo during infection [31]. To better understand this
association, we conducted functional and phenotypic studies in
vitro. Our group, using J774A.1 macrophages (data not shown),
and others using primary human cells, have shown that
macrophages and monocytes are permissible to RSV and that
permissibility is greater in cord blood monocytes.adult mono-
cytes.adult macrophages, suggesting permissibility varies in
relation to macrophage maturity [38–42]. In a culture environ-
ment, with no environmental signals, we showed J774A.1
macrophages differentiated to an AAM phenotype following
RSV infection and mediated the spread of virus to adjacent
Hep-2 cells. However, when J774A.1 macrophages were primed
with IFNc prior to infection, they differentiated to a CAM
phenotype and the spread to Hep-2 cells was significantly reduced
compared to cells that were not primed. It is conceivable that these
in vitro studies closely model neonatal and adult airways following
RSV infection in that the neonatal airway is devoid of IFNc
leaving the fate of the AM phenotype at the hands of RSV, which
we showed differentiates to an AAM phenotype. Conversely, adult
airways are rich in IFNc during RSV infection, which lead to
CAM differentiation capable of intracellular killing, pro-inflam-
matory cytokine secretion, and initiation of the adaptive immune
response. These studies do not conclusively rule out the possibility
that reductions in viral load in vivo may be partially attributable to
the intrinsic anti-viral ‘‘interfering’’ properties of IFNc. However,
in our in vitro experiment design, RSV does not come in direct
contact with IFNc. Rather, J774A.1 macrophages are primed with
IFNc, the IFNc solution is removed, and then the cells are
infected. Additional control wells containing only RSV and rIFNc
showed no reduction in viral plaques, indicating that rIFNc was
activating macrophages to reduce the spread of infection to
adjacent HEP-2 cells. Together, these data show rIFNc stimulates
macrophages to prevent the spread of RSV infection.
In summary, these data show the neonatal response to RSV
infection depends on an abundant but immature AM population
that fails to express a CAM phenotype in the IFNc-deficient infant
lung environment. Despite their age-dependent phenotype,
treatment with i.n. IFNc induces a CAM phenotype characterized
by a significant reduction in MR, increases in MHC II, CD86, and
CCR7, coupled with significant increases in the macrophage-
derived cytokines, IL-12p40, IL-6, and TNFa. Treated mice
showed a log-fold reduction in viral lung titers, expedited RSV
clearance, and a significant increase in weight gain compared to
untreated mice. Our in vitro data further supports our hypothesis
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that IFNc-primed macrophages different to a CAM phenotype
and reduce the spread RSV infection. Taken together, these data
demonstrate i.n. IFNc, a product that is already commercially
available, is a viable treatment option and should be considered for
further studies in neonatal RSV disease.
Supporting Information
Figure S1 Neonatal BALB/cJ mice express an age-
dependent tissue macrophage phenotype following RSV
infection. Adult and pup BALB/cJ mice were infected with HD/
HV RSV line19 or cell lysate. Cells were isolated from pup and
adult digested lung tissue on 0, 2, 4, 7, and 10 dpi. The percent of
immune cell subtypes were analyzed by flow cytometry in adults
(A–D) pups (E–F), including MHC II (A, E), CD86 (B, F), CCR7
(C, G), and MR (D, H) on the CD11b2 CD11c+ high gate. Mean
values 6 SD are depicted, and statistical difference was defined as
a P value.05 for differences between mock-infected animals at the
same time point (*); data are representative of two separate
experiments.
(TIF)
Figure S2 Pro-inflammatory cytokines are increased in
RSV-infected neonatal mice following i.n. rIFN treat-
ment. Pup (2–4 days old) BALB/cJ mice received a HD/HV
inoculum of RSV line 19 followed by 16 ng/g of i.n. rIFNc (RSV/
rIFNc+) or diluent only (RSV/rIFNc2) on 1, 3, 5, and 7 dpi.
Control groups were mock-infected with cell lysate followed by
16 ng/g of i.n. rIFNc (mock/rIFNc+) or diluent only (mock/
rIFNc 2) on 1, 3, 5, and 7 dpi. Pups were lavaged with 1.5–3 ml
of cold HBSS/EDTA at the indicated dpi. The first wash of each
lavage was reserved and frozen for analysis by luminex multiplex
assay. Concentrations of IL-12p40 (A), IL-6 (B), and TNFa (C)
were measured 4 and 7 dpi; all points are above the assay’s LOQ.
Mean values 6 SD are depicted, and statistical difference was
defined as a P value.05 for differences between groups at the same
time point (*); data are representative of two separate experiments.
(TIF)
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